Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease
Main finding · Initiation of SGLT2i (prescription fill) at any pointResult — go to the resultHazard ratio 1.91 95% CI 1.69–2.16Authors' conclusion
In this quality improvement study, pharmacist-led outreach was associated with increased initiation of SGLT2 inhibitors; however, limited intervention reach may have constrained the overall impact. Strategies to improve uptake are needed to enhance impact and inform broader SGLT2 inhibitor implementation in patients with CKD and type 2 diabetes.
Study context
- Population
- Veterans with chronic kidney disease (CKD) (eGFR ≥25 and <60 mL/min/1.73 m²) and T2D, not already prescribed an SGLT2i, 8 Veterans Affairs (VA) health systems in the midwestern US; mean age 78.7 years, 96.7% male
- Participants
- 8,658 eligible patients
- Comparison
- Pharmacist-led outreach vs usual care
- Interventionn = 4,400
- Controln = 4,258reference
- Outcome
- Initiation of an SGLT2i, determined by prescription fill
- Follow-up
- Any point during the study
Methodological detailspseudorandomized treatment assignment (last digit of Social Security number), 8 VA health systems, Conducted February 2022 through April 2024
- Pseudorandomized treatment assignment (last digit of Social Security number)
- 8 VA health systems
- Conducted February 2022 through April 2024
Main finding
As reported in the abstract
Initiation of SGLT2i (prescription fill) at any point
Hazard ratio
1.91
95% CI 1.69–2.16
P < 0.001
Interventionvs Control
HR 1.91 (95% CI 1.69–2.16); P < 0.001
Secondary outcomes
Cumulative proportion of SGLT2i prescriptions filled · 1 year after group assignment
SGLT2i prescription fill · 12 months
| Outcome | Win ratio (95% CI) | P value | |
|---|---|---|---|
| Exploratory composite clinical outcome (all-cause mortality, kidney failure, HF, MI, stroke) | 1.02 (0.97–1.07) | P = 0.54 | |
| 0.512Win ratio (log scale) |
Original publication
Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease. JAMA Netw Open. Published 1 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →